Tyk2-IN-17, identified by its CAS number 3010874-31-1, is a selective inhibitor of the tyrosine kinase 2 (Tyk2) enzyme, which plays a crucial role in the signaling pathways of various cytokines involved in immune responses. This compound is primarily researched for its potential therapeutic applications in autoimmune diseases and inflammatory conditions, as Tyk2 is implicated in the pathogenesis of disorders such as psoriasis and rheumatoid arthritis. The characteristics of Tyk2-IN-17 include its molecular structure, which typically features specific functional groups that confer its inhibitory activity, and its pharmacokinetic properties, which influence its absorption, distribution, metabolism, and excretion in biological systems. Additionally, the compound's efficacy and safety profile are evaluated through preclinical and clinical studies to determine its potential as a treatment option. Overall, Tyk2-IN-17 represents a promising avenue in targeted therapy, aiming to modulate immune responses with reduced side effects compared to broader immunosuppressive agents.

Tyk2-IN-17

3010874-31-1: Tyk2-IN-17, identified by its CAS number 3010874-31-1, is a selective inhibitor of the tyrosine kinase 2 (Tyk2) enzyme, which plays a crucial role in the signaling pathways of various cytokines involved in immune responses. This compound is primarily researched for its potential therapeutic applications in autoimmune diseases and inflammatory conditions, as Tyk2 is implicated in the pathogenesis of disorders such as psoriasis and rheumatoid arthritis. The characteristics of Tyk2-IN-17 include its molecular structure, which typically features specific functional groups that confer its inhibitory activity, and its pharmacokinetic properties, which influence its absorption, distribution, metabolism, and excretion in biological systems. Additionally, the compound's efficacy and safety profile are evaluated through preclinical and clinical studies to determine its potential as a treatment option. Overall, Tyk2-IN-17 represents a promising avenue in targeted therapy, aiming to modulate immune responses with reduced side effects compared to broader immunosuppressive agents.

<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>

CAS 3010874-31-1

Tyk2-IN-17

Tyk2-IN-17

Ref: TM-T87586